Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline has received European approval to market its hepatitis B vaccine, Fendrix. The approval has raised shares in Corixa Corporation, which developed the adjuvant contained in the vaccine, by 2%.
Subscribe to our email newsletter
Fendrix contains the GSK hepatitis B antigen and a novel proprietary GSK adjuvant system, AS04, which includes MPL from Corixa developed to have a higher potency than other available hepatitis vaccines, resulting in higher, more rapid and longer-lasting seroprotection.
Fendrix is designed to prevent hepatitis B in patients with renal insufficiency, including specific high-risk groups such as pre-haemodialysis and haemodialysis patients, and builds on the experience of hepatitis B vaccine predecessor Engerix B.
“Today’s product approval marks another significant commercialization milestone for our adjuvant business,” said Steven Gillis, chairman and CEO of Corixa. “Given that our MPL adjuvant is a component of several additional GSK vaccines now in late-stage clinical trials, we look forward to the growth of our adjuvant business and its potential contribution to Corixa’s future product sales and royalty income.”